Key Points
- Rameda Pharmaceuticals' sales to government tenders declined by 63% to EGP 89 million in Q3 2026.
- The decline was driven by a 64% decrease in sales volume to 3.1 million units.
- Exports grew by 10% to EGP 68 million in Q3 2026, driven by strong demand in Afghanistan and Iraq.
Rameda's Sales Decline and Export Growth
Rameda Pharmaceuticals, an Egyptian pharmaceuticals manufacturer, reported a 63% decline in sales to government tenders to EGP 89 million in Q3 2026. This decline was driven by a 64% decrease in sales volume to 3.1 million units. In contrast, exports grew by 10% to EGP 68 million in Q3 2026, driven by strong demand in Afghanistan and Iraq.
The company attributed this growth to its strong performance in the Afghan market, where sales increased to EGP 23 million, up from less than EGP 1 million in Q3 2025. Additionally, Rameda reported increased sales in Iraq and expansion into new markets, including the UAE and Azerbaijan.
At a Glance
| Main Company | Rameda Pharmaceuticals Egyptian pharmaceuticals manufacturer |
| Main Executive | Not specified No executive mentioned in the article |
| Organization | Egyptian Ministry of Health Government agency responsible for healthcare |
| Regulator | Egyptian Unified Procurement Authority (UPA) Government agency responsible for public procurement |
| Location | Egypt Country of operation |
| Country | Egypt Country of operation |
| Industry | Pharmaceuticals Industry sector |
| Key Product/Service | Pharmaceuticals Main product/service offered by Rameda |
| Key Financial Figure | EGP 89 million Decline in government tenders sales |
| Key Date | Q3 2026 Quarter under review |
Behind Rameda's Q3 2026 Performance
Behind Rameda's Q3 2026 Performance
The decline in government tenders sales was a significant factor in Rameda's Q3 2026 performance. However, the company's exports growth was driven by strong demand in key markets, including Afghanistan and Iraq.
Rameda's performance in these markets was attributed to the company's strong product offerings and its ability to adapt to changing market conditions.
What This Means for Investors and Competitors
What This Means for Investors and Competitors
For investors, Rameda's decline in government tenders sales is a concern, as it may impact the company's revenue growth. However, the company's exports growth is a positive sign, indicating its ability to adapt to changing market conditions.
For competitors, Rameda's performance in key markets, including Afghanistan and Iraq, is a challenge, as it may impact their market share.
Comments 0